Novo Nordisk’s weekly GLP-1 diabetes injection semaglutide has been approved by the US regulator, a potential blockbuster that the firm hopes will allow it to regain market share from Lilly
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
